Radiopharm Theranostics Limited (AU:RAD) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Radiopharm Theranostics Limited has announced a strategic partnership with Lantheus to co-develop innovative radiopharmaceuticals in Australia, focusing initially on a Phase 1 imaging trial for multiple solid tumors. Under this agreement, Lantheus will fund all clinical development costs, while Radiopharm stands to gain up to USD 2 million upon achieving specific clinical milestones. This collaboration highlights both companies’ dedication to advancing oncology treatments and addressing unmet medical needs.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.